Breast Care最新文献_第7页

Front & Back Matter 正面和背面

IF 2.1 4区医学

Breast Care Pub Date : 2021-12-01 DOI: 10.1159/000521407

B. Gulluoglu, S. Corradini

引用次数: 0

Front & Back Matter 正面和背面

IF 2.1 4区医学

Breast Care Pub Date : 2021-10-01 DOI: 10.1159/000520067

B. Gulluoglu, S. Corradini

引用次数: 0

PharmaNews PharmaNews

IF 2.1 4区医学

Breast Care Pub Date : 2021-10-01 DOI: 10.1159/000519989

引用次数: 0

Physicians’ Perception of the Evidence in Relation to Primary Endpoints of Clinical Trials on Breast Cancer 医生对乳腺癌临床试验主要终点相关证据的认知

IF 2.1 4区医学

Breast Care Pub Date : 2021-08-20 DOI: 10.1159/000518260

Yi Zhang, Miao Liu, Houpu Yang, Shu Wang

{"title":"Physicians’ Perception of the Evidence in Relation to Primary Endpoints of Clinical Trials on Breast Cancer","authors":"Yi Zhang, Miao Liu, Houpu Yang, Shu Wang","doi":"10.1159/000518260","DOIUrl":"https://doi.org/10.1159/000518260","url":null,"abstract":"Objective: To investigate physicians’ perception of the evidence of clinical trials on breast cancer. Methods: A survey was conducted by the Chinese Society of Breast Surgeons. We investigated the physicians’ perception of meaningful endpoints, appropriate follow-up duration, and clinically acceptable benefit through online questionnaires. Results: Among 278 validated questionnaires, the majority of the questions had no consistent answer. For local treatment, 30.6, 28.8, and 28.4% of participants regarded locoregional recurrence (LRR), disease-free survival (DFS), and overall survival (OS) as the most meaningful endpoint, respectively, 47.5% believed that 5-year follow-up can alter clinical practice, and 34.5% thought it should be >10 years. In the adjuvant setting, 45.7, 38.5, and 12.9% regarded DFS, OS, and LRR as the most meaningful endpoint, respectively, 52.5% thought that 10-year follow-up was solid, while 37.4% thought that 5-year follow-up was enough. In the advanced setting, 49.6, 24.1, and 23.7% considered progression-free survival, quality of life, and OS the most meaningful endpoint, respectively, and 39.6 and 28.8% considered that a follow-up of 1 year and 3 years, respectively, was meaningful. Similarly, the clinically acceptable absolute difference was inconsistent. Conclusion: Most Chinese oncologists advocated that surrogate endpoints could be used in certain circumstances, though OS was the most reliable one in breast cancer studies. Doctors’ perceptions of follow-up time and magnitude of benefit vary widely, reflecting the fact that there are many unanswered questions about supporting the use of new cancer treatments; a common understanding needs to be reached, such as a very consensual surrogate endpoint and a meaningful sufficiently large therapeutic benefit.","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":"17 1","pages":"180 - 187"},"PeriodicalIF":2.1,"publicationDate":"2021-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45190843","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Risk-Adjusted Cancer Screening and Prevention (RiskAP): Complementing Screening for Early Disease Detection by a Learning Screening Based on Risk Factors 风险调整的癌症筛查和预防（RiskAP）：基于风险因素的学习筛查对早期疾病检测的补充筛查

IF 2.1 4区医学

Breast Care Pub Date : 2021-08-12 DOI: 10.1159/000517182

R. Schmutzler, Björn Schmitz-Luhn, B. Borisch, P. Devilee, D. Eccles, P. Hall, J. Balmaña, S. Boccia, P. Dabrock, G. Emons, W. Gaissmaier, J. Gronwald, S. Houwaart, S. Huster, K. Kast, A. Katalinic, S. Linn, S. Moorthie, P. Pharoah, K. Rhiem, T. Spranger, D. Stoppa-Lyonnet, J. V. van Delden, M. Van den Bulcke, C. Woopen

{"title":"Risk-Adjusted Cancer Screening and Prevention (RiskAP): Complementing Screening for Early Disease Detection by a Learning Screening Based on Risk Factors","authors":"R. Schmutzler, Björn Schmitz-Luhn, B. Borisch, P. Devilee, D. Eccles, P. Hall, J. Balmaña, S. Boccia, P. Dabrock, G. Emons, W. Gaissmaier, J. Gronwald, S. Houwaart, S. Huster, K. Kast, A. Katalinic, S. Linn, S. Moorthie, P. Pharoah, K. Rhiem, T. Spranger, D. Stoppa-Lyonnet, J. V. van Delden, M. Van den Bulcke, C. Woopen","doi":"10.1159/000517182","DOIUrl":"https://doi.org/10.1159/000517182","url":null,"abstract":"Background: Risk-adjusted cancer screening and prevention is a promising and continuously emerging option for improving cancer prevention. It is driven by increasing knowledge of risk factors and the ability to determine them for individual risk prediction. However, there is a knowledge gap between evidence of increased risk and evidence of the effectiveness and efficiency of clinical preventive interventions based on increased risk. This gap is, in particular, aggravated by the extensive availability of genetic risk factor diagnostics, since the question of appropriate preventive measures immediately arises when an increased risk is identified. However, collecting proof of effective preventive measures, ideally by prospective randomized preventive studies, typically requires very long periods of time, while the knowledge about an increased risk immediately creates a high demand for action. Summary: Therefore, we propose a risk-adjusted prevention concept that is based on the best current evidence making needed and appropriate preventive measures available, and which is constantly evaluated through outcome evaluation, and continuously improved based on these results. We further discuss the structural and procedural requirements as well as legal and socioeconomical aspects relevant for the implementation of this concept.","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":"17 1","pages":"208 - 223"},"PeriodicalIF":2.1,"publicationDate":"2021-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46321367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 5

PharmaNews PharmaNews

IF 2.1 4区医学

Breast Care Pub Date : 2021-08-01 DOI: 10.1159/000518907

引用次数: 0

Front & Back Matter 正面和背面

IF 2.1 4区医学

Breast Care Pub Date : 2021-08-01 DOI: 10.1159/000519184

B. Gulluoglu, V. Hanf

引用次数: 0

Consensus Recommendations of the German Consortium for Hereditary Breast and Ovarian Cancer 德国遗传性乳腺癌和卵巢癌协会的共识建议

IF 2.1 4区医学

Breast Care Pub Date : 2021-07-19 DOI: 10.1159/000516376

K. Rhiem, B. Auber, S. Briest, N. Dikow, N. Ditsch, Neda Dragicevic, S. Grill, E. Hahnen, J. Horváth, B. Jaeger, K. Kast, M. Kiechle, E. Leinert, S. Morlot, M. Püsken, Dieter Schäfer, S. Schott, C. Schroeder, U. Siebers-Renelt, C. Solbach, N. Weber-Lassalle, I. Witzel, C. Zeder-Göss, R. Schmutzler

引用次数: 10

Factors Indicating Surgical Excision in Classical Type of Lobular Neoplasia of the Breast 典型乳腺小叶性肿瘤手术切除的因素分析

IF 2.1 4区医学

Breast Care Pub Date : 2021-07-07 DOI: 10.1159/000516609

C. Elfgen, C. Tausch, A. Rodewald, U. Güth, C. Rageth, V. Bjelic-Radisic, M. Fleisch, C. Kurtz, J. Gonzalez Diaz, Z. Varga

{"title":"Factors Indicating Surgical Excision in Classical Type of Lobular Neoplasia of the Breast","authors":"C. Elfgen, C. Tausch, A. Rodewald, U. Güth, C. Rageth, V. Bjelic-Radisic, M. Fleisch, C. Kurtz, J. Gonzalez Diaz, Z. Varga","doi":"10.1159/000516609","DOIUrl":"https://doi.org/10.1159/000516609","url":null,"abstract":"Purpose: Classical type of lobular neoplasia (LN) encompassing both atypical lobular hyperplasia and classical lobular carcinoma in situ of the breast is a lesion with uncertain malignant potential and has been the topic of several studies with conflicting outcome results. The aim of our study was to clarify outcome-relevant factors and treatment options of classical LN. Methods: We performed a pathological re-evaluation of the preoperative biopsy specimens and a retrospective clinical and radiological data analysis of 160 patients with LN from the Breast Center Zurich. Open surgery was performed in 65 patients, vacuum-assisted biopsy (VAB) in 79 patients, and surveillance after breast core needle biopsy (CNB) in 16 patients. Results: The upgrade rate into ductal carcinoma in situ/invasive cancer was the highest in case of imaging/histology discordance (40%). If the number of foci in the biopsy specimen was ≥3, the upgrade rate in the consecutive surgical specimens was increased (p = 0.01). The association of classical LN with histological microcalcification correlated with shortened disease-free survival (p < 0.01), whereas other factors showed no impact on follow-up. Conclusions: Surveillance or subsequent VAB after CNB of LN is sufficient in most cases. Careful consideration of individual radiological and histological factors is required to identify patients with a high risk of upgrade into malignancy. In those cases, surgical excision is indicated.","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":"17 1","pages":"121 - 129"},"PeriodicalIF":2.1,"publicationDate":"2021-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000516609","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48977029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 5

Malignancy Rate and Malignancy Risk Assessment in Different Lesions of Uncertain Malignant Potential in the Breast (B3 Lesions): An Analysis of 192 Cases from a Single Institution 乳腺不同恶性潜能不确定病变(B3型病变)的恶性发生率及恶性风险评估:来自某机构192例病例分析

IF 2.1 4区医学

Breast Care Pub Date : 2021-07-01 DOI: 10.1159/000517109

S. Mohrmann, Anna Maier-Bode, F. Dietzel, P. Reinecke, N. Krawczyk, T. Kaleta, U. Kreimer, G. Antoch, T. Fehm, Katrin Roth

{"title":"Malignancy Rate and Malignancy Risk Assessment in Different Lesions of Uncertain Malignant Potential in the Breast (B3 Lesions): An Analysis of 192 Cases from a Single Institution","authors":"S. Mohrmann, Anna Maier-Bode, F. Dietzel, P. Reinecke, N. Krawczyk, T. Kaleta, U. Kreimer, G. Antoch, T. Fehm, Katrin Roth","doi":"10.1159/000517109","DOIUrl":"https://doi.org/10.1159/000517109","url":null,"abstract":"Background: The question of how to deal with B3 lesions is of emerging interest. Methods: In the breast diagnostics of 192 patients between 2009 and 2016, a minimally invasive biopsy revealed a B3 lesion with subsequent resection. This study investigates the malignancy rate of different B3 subgroups and the risk factors that play a role in obtaining a malignant finding. Results: The distribution of B3 lesions after minimally invasive biopsy was as follows: atypical ductal hyperplasia (ADH), 7.3%; flat epithelial atypia (FEA), 7.8%; lobular neoplasia (LN), 7.8%; papilloma (Pa), 49.5%; phylloidal tumour (PT), 8.9%; radial sclerosing scar (RS), 3.1%; mixed findings, 10.4%; and other B3 lesions, 5.2%. Most B3 lesions were detected by stereotactic vacuum-assisted biopsy (44.3%), 36.5% by ultrasound-assisted biopsy, and 19.3% by magnetic resonance imaging-assisted biopsy. Most B3 lesions (55.2%) were verified by surgical resection, whereas 30.7% were downgraded to a benign lesion. About 14.1% of the cases were upgraded to malignant lesions, 9.4% to ductal carcinoma in situ and 4.7% to invasive carcinoma. In relation to individual B3 lesions, the following malignancy rates were found: 28.6% (ADH), 13.3% (FEA), 33.3% (LN), 12.6% (Pa), 5.9% (PT), and 0% (RS). The most important risk factor was increasing age. Postmenopausal status was considered an increased risk for an upgrade (p = 0.015). A known malignancy in the ipsilateral breast was a significant risk factor for a malignant upgrade (p = 0.003). Conclusion: Increasing knowledge about B3 lesions allows us to develop a “lesion-specific” therapy approach in the heterogeneous group of B3 lesions, with follow-up imaging for some lesions with less malignant potential and concordance with imaging or further surgical resection in cases of disconcordance with imaging or higher malignant potential.","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":"17 1","pages":"159 - 165"},"PeriodicalIF":2.1,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000517109","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44651365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 5